ClinicalTrials.gg
Not yet recruitingNCT06657170Updated Dec 12, 2024

Hidden Slow Conduction Ablation for Recurrent Atrial Fibrillation: Unmasking the Arrhythmogenic Substrate (Unmask-AF)

An interventional study of Pulmunary veins reconnection plus hidden slow conduction ablation and Pulmunary veins (PV) reconnection ablation only in Atrial Fibrillation, sponsored by Centro Medico Teknon. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Centro Medico Teknon · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Over recent years, pulmonary vein isolation (PVI) procedures have demonstrated progressively enhanced efficacy and safety, resulting in a substantial increase in the number of atrial fibrillation ablations, not only as a first-line treatment but also for repeat procedures. However, there is still a notable lack of randomized evidence in this area, which limits guidance and decision-making in clinical practice. Recently, the investigators found that employing short-coupled atrial extrastimuli revealed highly fragmented or double atrial evoked electrograms (EGMs) in AF patients, termed as hidden slow conduction (HSC). Identifying HSC sites may provide insight into the early identification of the arrhythmogenic substrate, offering a potential target for ablation This multi-center, prospective, randomized, controlled trial will include two arms: one investigational (PV reconnection + HSC) and one control (PV reconnection). All the subjects will be followed for 12 months after the ablation procedure.

The aim of our study is to investigate the impact of ablating HSC sites on arrhythmia recurrence in repeat ablation procedures. The hypothesis is that the additional ablation of HSC zones may improve the freedom from atrial arrhythmia recurrence after repeat ablation procedure.

02

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Catheter Ablation
  • Re-do Procedures
  • Hidden Slow Conduction
  • Functional Substrate Ablation
03

In context

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

This study's planned enrollment of 212 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Centro Medico Teknon is the lead sponsor of 20 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent paroxysmal AF (continuous AF episode lasting longer than 30 s but terminating spontaneously or with intervention within 7 days of onset), recurrent persistent AF (continuous AF episode lasting longer than 7 days but \< 1 year) and recurrent long standing persistent AF (continuous AF ≥1 year in duration, in patients where rhythm control management is being pursued)
  • Previous PVI procedure
  • Age > 40 years
  • Willing and capable of providing consent
  • Able and willing to comply with all follow-up testing and requirements

Exclusion criteria

Exclusion Criteria:

  • Additional left atrial ablations during the previous procedures (es. posterior wall isolation, anterior line, roof line, CFAE and others)
  • Acute illness, active systemic infection, or sepsis
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation.
  • Severe mitral regurgitation
  • Women who are pregnant, lactating, or who are planning to become pregnant during the course of the clinical investigation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    PV reconnection + HSC ablation

    Patients undergoning pulmunary veins (PV) reconnection checking and ablation plus identification and ablation of hidden sites of slow conduction (HSC)

    Procedure: Pulmunary veins reconnection plus hidden slow conduction ablation

  • Active comparator
    PV reconnection ablation only

    Patients undergoning PV reconnection checking and ablation only.

    Procedure: Pulmunary veins (PV) reconnection ablation only

Interventions

  • ProcedurePulmunary veins reconnection plus hidden slow conduction ablation

    Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium. HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm. After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed. The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms).

  • ProcedurePulmunary veins (PV) reconnection ablation only

    Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).

06

What researchers measure

Primary outcomes

  1. Atrial arrhythmias recurrence

    The primary endpoint of the study aims to establish the impact of targeting HSC sites alongside PV gaps in repeat ablation procedures for patients with recurrent AF. Specifically evaluating the freedom from atrial tachyarrhythmia recurrence (documented AF/AT/AFL lasting at least 30s).

    Time frame: up to 12 moths

Secondary outcomes

  1. Burden of atrial arrhythmias

    Arrhythmic burden (average percentage of time in AF/AT in 24h Holter)

    Time frame: up to 12 moths

  2. incidence of periprocedural complications (pericardial effusion)

    incidence of periprocedural complications such as pericardial effusion

    Time frame: up to 12 months

  3. Use of antiarrhythmic drugs

    Use of antiarrhythmic drugs after the blanking period of 60 days.

    Time frame: up to 12 months

  4. incidence of periprocedural complications (peripheral complication)

    incidence of periprocedural complications such as peripheral complication

    Time frame: up to 12 moths

  5. incidence of periprocedural complications (transient ischemic attack or stroke)

    incidence of periprocedural complications such as transient ischemic attack or stroke

    Time frame: up to 12 months

Other outcomes

  1. Concentration of intramyocardial fat (inFAT) into the HSC points

    Concentration of intramyocardial fat (inFAT) into the atrial area where we found the HSC points

    Time frame: up to 12 months

  2. Procedure features

    procedure time

    Time frame: up to 12 months

  3. Atrial arrhythmias first recurrence

    Evaluation of the atrial arrhythmias recurrence in patients with isolated PVs underwent HSC sites ablation

    Time frame: up to 12 months

  4. Left atrial wall thickness (LAWT) measurement into the HSC points

    Left atrial wall thickness (LAWT) measurement into the atrial areas where we found the HSC points

    Time frame: up to 12 months

  5. procedure features

    fluoroscopy time

    Time frame: up to 12 months

  6. procedure features

    fluoroscopy dose

    Time frame: up to 12 months

  7. procedure features

    number of radiofrequency (RF) applications

    Time frame: up to 12 months

  8. procedure times

    radiofrequency (RF) total delivery time

    Time frame: up to 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pokushalov E, Romanov A, De Melis M, Artyomenko S, Baranova V, Losik D, Bairamova S, Karaskov A, Mittal S, Steinberg JS. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. Circ Arrhythm Electrophysiol. 2013 Aug;6(4):754-60. doi: 10.1161/CIRCEP.113.000495. Epub 2013 Jun 7. PubMed 23748210 ↗
  • Saglietto A, Falasconi G, Soto-Iglesias D, Francia P, Penela D, Alderete J, Viveros D, Bellido AF, Franco-Ocana P, Zaraket F, Turturiello D, Marti-Almor J, Berruezo A. Assessing left atrial intramyocardial fat infiltration from computerized tomography angiography in patients with atrial fibrillation. Europace. 2023 Dec 6;25(12):euad351. doi: 10.1093/europace/euad351. PubMed 38011712 ↗
  • Silva Garcia E, Lobo-Torres I, Fernandez-Armenta J, Penela D, Fernandez-Garcia M, Gomez-Lopez A, Soto-Iglesias D, Fernandez-Rivero R, Vazquez-Garcia R, Acosta J, Bisbal F, Cano-Calabria L, Berruezo A. Functional mapping to reveal slow conduction and substrate progression in atrial fibrillation. Europace. 2023 Nov 2;25(11):euad246. doi: 10.1093/europace/euad246. PubMed 37961921 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Sep 2026, 21 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 21 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Oct 24, 2024
StartEst.
Dec 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2027
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06657170
Lead sponsor
Centro Medico Teknon
Responsible party
Antonio Berruezo, MD, PhD (Director of Electrophysiology unit, Centro Medico Teknon) — Principal investigator
First posted
Oct 24, 2024
Start date
Dec 2024 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Dec 12, 2024

Study contacts

Antonio Berruezo Sanchez, MD, PHD
Contact
antonio.berruezo@quironsalud.es
3384090290

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion